Published in Drug Week, February 13th, 2004
Under the terms of the agreement, Dyax and Baxter will conduct a research program to identify and characterize antibodies that bind specifically to MIF and neutralize its activity. MIF is a cytokine involved in immune, infectious, and malignant disorders. Neutralizing MIF activity may be useful in the treatment of a wide spectrum of diseases, including...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.